Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 2
2(50.0%)
4Total
Phase 1(2)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01930240Phase 1Completed

The Safety of a Hypolipidemic Agent in Healthy Normal Volunteers

Role: lead

NCT02008084Phase 2Completed

A Pilot Study to Evaluate the Lipid Effects of TRIA-662

Role: lead

NCT00758303Phase 2Completed

A Study to Evaluate the Lipid Regulating Effects of TRIA-662

Role: lead

NCT01809301Phase 1Completed

Comparison of TRIA-662 500 mg and Niaspan 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions

Role: lead

All 4 trials loaded